Sergey Brin folds $200M brain-health VC fund into family office as neuro bets top $2B
What's the deal? Sergey BrinDealroom has a profile for this one. Try Dealroom →'s family office, Bayshore Global Management, has absorbed Nexus NeuroTech VenturesDealroom has a profile for this one. Try Dealroom →, a brain-health venture capital fund that the Google co-founder backed. Nexus managed over $200 million and held 15 portfolio companies focused on therapies for nervous system disorders — including a wristband that reduces hand tremors and an ultrasound device that modifies brain activity. The fund shut down on March 31, and its assets now sit inside Bayshore.
"Through a recent acquisition, Nexus NeuroTech Ventures has concluded its operations," former chief executive officer Jordi Parramon wrote on LinkedIn.
Why now? The move consolidates Brin's growing neuroscience bets under one roof. Through his nonprofit Catalyst4, Brin has poured over $600 million into startups and venture funds developing for-profit treatments for brain diseases — about $400 million of that in 2024 alone. He donated more than $1.1 billion in Alphabet stock last year, with roughly $1 billion going to Catalyst4.
Brin's interest is deeply personal. His mother, who had Parkinson's disease, died in December at age 76. He carries a genetic mutation that raises his own risk. He has spent $1.75 billion on Parkinson's research — more than any other individual.
His ambitions are widening. In early 2022, his team began planning an autism research initiative called ARIA, which has received nearly $50 million so far. Brin has also backed $75 million in bipolar disorder research through a separate effort called BD2.
What could go wrong? Brain science is notoriously slow and expensive. "It's so difficult to work within the human brain, because you don't have access to it," said UC Berkeley biochemist Robert Tjian, an adviser at The Column Group, a biotech VC firm that manages a $200 million Brin-backed fund. Timelines from initial investment to clinical results stretch far beyond what most VCs tolerate. "You're going to have to be lucky," Tjian added.
Folding a standalone fund into a family office also removes some external oversight. Catalyst4, a 501(c)(4) nonprofit, owned about 95% of Nexus and controls stakes in several other funds — a structure that keeps decision-making close to Brin but limits outside accountability.
The signal: The world's wealthiest people are increasingly treating neuroscience as a frontier worth billions. Elon MuskDealroom has a profile for this one. Try Dealroom →, Jeff BezosDealroom has a profile for this one. Try Dealroom → and Bill GatesDealroom has a profile for this one. Try Dealroom → have all backed brain-technology ventures. Brin's approach — blending philanthropy, venture capital, and a family office — is among the most ambitious. With nearly $2 billion committed to brain research and a growing portfolio of biopharma bets, he is betting that private capital can push a field where public funding and traditional VC have struggled to make headway.
Sources:
Bloomberg
Forbes
Lifestyles Magazine
Image Credit: James Duncan Davidson/O'Reilly Media, Wikimedia Commons
B.S.
